Join Growin Stock Community!

Xenon pharmaceuticals inc.XENE.US Overview

US StockHealthcare
(No presentation for XENE)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

XENE AI Insights

XENE Overall Performance

XENE AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

XENE Recent Performance

-0.71%

Xenon pharmaceuticals inc.

-3.61%

Avg of Sector

-2.16%

S&P500

XENE PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

XENE Key Information

XENE Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

XENE Profile

Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other potential indications, including adult focal epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in Phase II clinical trials. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy; and with Flexion Therapeutics, Inc. to develop PCRX301 (XEN402, a Nav1.7 inhibitor) for the treatment of post-operative pain. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

Price of XENE

XENE FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

XENE Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-4.48
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
445.41
PB Ratio
6.20
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
100.00%
Net Margin
-4612.13%
Revenue Growth (YoY)
-100.00%
Profit Growth (YoY)
-100.00%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-4.48
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
445.41
PB Ratio
6.20
Price-to-FCF
-
Gross Margin
100.00%
Net Margin
-4612.13%
Revenue Growth (YoY)
-100.00%
Profit Growth (YoY)
-100.00%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%

  • When is XENE's latest earnings report released?

    The most recent financial report for Xenon pharmaceuticals inc. (XENE) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating XENE's short-term business performance and financial health. For the latest updates on XENE's earnings releases, visit this page regularly.

  • How much debt does XENE have?

    As of the end of the reporting period, Xenon pharmaceuticals inc. (XENE) had total debt of 7.94M, with a debt ratio of 0.01. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does XENE have?

    At the end of the period, Xenon pharmaceuticals inc. (XENE) held Total Cash and Cash Equivalents of 199.16M, accounting for 0.31 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is XENE's EPS continuing to grow?

    According to the past four quarterly reports, Xenon pharmaceuticals inc. (XENE)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -1.31. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of XENE?

    Xenon pharmaceuticals inc. (XENE)'s Free Cash Flow (FCF) for the period is -81.8M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 48.27% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of XENE?

    The latest valuation data shows Xenon pharmaceuticals inc. (XENE) has a Price-To-Earnings (PE) ratio of -10.8 and a Price/Earnings-To-Growth (PEG) ratio of -0.61. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.